Jaruhathai Sureerat, Phornvoranunt Uraree, Wannasirikul Waran
Department of Internal Medicine, Police General Hospital, Bangkok, Thailand.
Department of Internal Medicine, Chaophya Hospital, Bangkok, Thailand.
Case Rep Oncol. 2021 Jun 17;14(2):918-921. doi: 10.1159/000516032. eCollection 2021 May-Aug.
Capecitabine is an oral chemotherapy that is used to treat several cancer types, including breast, gastrointestinal, hepatobiliary, and ovarian. The use of antimetabolites in cancer therapy has generally not been associated with leukemogenesis. In this report, we demonstrate a case of capecitabine-related acute myeloid leukemia that was diagnosed 16 months after the completion of treatment for early-stage colon cancer, by a complex chromosome analysis 48,XY,6,del(7)(q22),+8,+13,t(13;17)(q12;p13),t(13,21)(q12;122),+mar [Gazi Med J. 2018 Jan;29(1):57-58]. This is the first report to our knowledge of the development of t-AML in a patient with early-stage colon cancer that was caused by capecitabine. We should use capecitabine with caution. Further studies are essential to investigate capecitabine-triggered leukemogenesis.
卡培他滨是一种口服化疗药物,用于治疗多种癌症类型,包括乳腺癌、胃肠道癌、肝胆癌和卵巢癌。在癌症治疗中使用抗代谢物通常与白血病发生无关。在本报告中,我们展示了一例与卡培他滨相关的急性髓系白血病病例,该病例在早期结肠癌治疗结束16个月后被诊断出来,通过复杂染色体分析显示为48,XY,6,del(7)(q22),+8,+13,t(13;17)(q12;p13),t(13,21)(q12;122),+mar [《加济安泰普医学杂志》2018年1月;29(1):57 - 58]。据我们所知,这是首例关于早期结肠癌患者因卡培他滨导致治疗相关急性髓系白血病的报告。我们应谨慎使用卡培他滨。进一步的研究对于调查卡培他滨引发的白血病发生至关重要。